One step closer to a DNA vaccine against dengue virus

June 29, 2017, Frontiers
A TEM micrograph showing Dengue virus virions (the cluster of dark dots near the center). Image: CDC

In a new study, researchers inoculated mice with a new DNA vaccine candidate (pVAX1-D1ME) in order to evaluate its efficiency. They found that the vaccine candidate was able to induce persistent humoral and cellular immune responses and provided efficient protection against lethal challenge from one of the four serotypes of dengue virus (DV1). They also evaluated the immunoprotective potential of a combined (bivalent) DNA vaccine, which was found to generate a balanced immunogenic response to two serotypes of dengue virus (DV1 & DV2). These results are encouraging for the future development of a tetravalent vaccine that could provide efficient protection against all four serotypes of the virus.

"Our DNA candidate induced effective immune responses and protection in mice. Importantly, the bivalent vaccine generated a balanced immunity against DV1 and DV2 infection, which emits light for development of new type of tetravalent vaccine against dengue viruses," says corresponding author Dr. Jing An (Capital Medical University, China). "However, it was noted that the end-point titers of anti-DV1 and anti-DV2 in the bivalent vaccine-immunized mice were lower than those in the monovalent vaccine-immunized mice, indicating interference between the DV1 and DV2 vaccine candidates. This evidence should be considered in further research on tetravalent vaccine."

Dengue is a mosquito-borne pathogen that causes (DF) - one of the most rapidly spreading mosquito-borne diseases worldwide according to the WHO. Although the recombinant, live, attenuated, tetravalent dengue vaccine (CYD-TDV) has been approved for use in some countries, the vaccine appears to increase the risk of severe dengue in younger vaccine recipients. Thus, it is still necessary to develop safer, more economical and effective vaccines against dengue infection specifically.

"As a major public health problem, dengue is considered to be one of the fastest growing epidemics. Among the four distinct serotypes of dengue viruses (DV1-4), DV1 and DV2 are especially predominant serotypes," explains Dr. An. "In 2014, the Guangdong province of China suffered from the most serious dengue outbreak in its history and co-circulation of DV1 and DV2 was identified. Dengue became endemic in China - its prevention is a long-term effort.

DNA vaccination is a novel and rapidly developing approach for prevention and therapy of disease, which utilizes genetically modified plasmids with added genetic sequences that encode specific antigens and allows the body to produce them. Although this method is still in development and no licensed DNA vaccine is currently available for humans, it would offer a number of potential advantages including inexpensiveness, improved vaccine stability and ease of production. Dr. An and the research team are hoping that their research will pave the path for further advances in the research for a vaccine against all four serotypes of dengue virus.

"We are developing a tetravalent DNA vaccine and evaluating the immunogenicity in animal models," says Dr. An. "Finally, we try to translate the DNA vaccine candidates for further clinical application. Our preliminary research data are open, and we would like the results to be used by not only universities and researchers, but also by companies for further cooperation."

Explore further: Nanoparticle vaccinates mice against dengue fever

More information: Xiaoyan Zheng et al, Effective Protection Induced by a Monovalent DNA Vaccine against Dengue Virus (DV) Serotype 1 and a Bivalent DNA Vaccine against DV1 and DV2 in Mice, Frontiers in Cellular and Infection Microbiology (2017). DOI: 10.3389/fcimb.2017.00175

Related Stories

Nanoparticle vaccinates mice against dengue fever

October 20, 2016
Every year, more than 350 million people in over 120 countries contact dengue fever, which can cause symptoms ranging from achy muscles and a skin rash to life-threatening hemorrhagic fever. Researchers have struggled to ...

A protein vaccine designed to target all four variations of the dengue virus proves effective in mouse trials

September 11, 2015
A breakthrough in the search for safe immunization against dengue fever has emerged after trials at A*STAR showed a new vaccine without live viruses induces an effective immune response.

First dengue vaccine goes on sale in Guatemala

November 22, 2016
The world's first vaccine against dengue, a mosquito-borne virus that causes fever and pain and can be fatal, will go on sale in Guatemala within weeks, the French company making it said Tuesday.

Dengue vaccine enters phase 3 trial in Brazil

January 14, 2016
A large-scale clinical trial to evaluate whether a candidate vaccine can prevent the mosquito-borne illness dengue fever has been launched in Brazil. The vaccine, TV003, was developed by scientists in the laboratory of Stephen ...

Development of a novel vaccine for Zika

June 5, 2017
Research presented by Farshad Guirakhoo, Ph.D., Chief Scientific Officer, GeoVax, Inc., at the ASM Microbe 2017 meeting showed a new Zika virus vaccine that gives 100% protection in mice. The vaccine is the first to be based ...

Concerns over cost of dengue vaccine lessened with new study

June 28, 2012
Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million ...

Recommended for you

Cancer drug helps treat tuberculosis by restoring leaky blood vessels

April 26, 2018
Biomedical engineers have discovered an unlikely potential ally in the global fight against tuberculosis—an FDA-approved drug originally designed to treat cancer.

Molecule may help tame virulent bacteria and prevent infection

April 26, 2018
According to the U.S. Centers for Disease Control and Prevention, about one in three humans carries Staphylococcus aureus, or "staph," in our noses, and 2 percent of us carry the dreaded methicillin-resistant (MRSA) strain ...

Antibody 'cocktail' can prevent Zika infection but is not effective for treatment of fetuses

April 26, 2018
A "cocktail" of monoclonal antibodies that can prevent Zika virus (ZIKV) infection in primates was not effective for treatment of fetuses, according to a new collaborative study led by a University of Miami Miller School ...

E. coli—are we measuring the wrong thing?

April 25, 2018
A sepsis awareness and management programme has demonstrated overall success in terms of improved sepsis detection, but has led to an increase in the number of E. coli blood stream infection cases presented, calling into ...

Malaria study reveals gene variants linked to risk of disease

April 25, 2018
Many people of African heritage are protected against malaria by inheriting a particular version of a gene, a large-scale study has shown.

Commonly prescribed heartburn drug linked to pneumonia in older adults

April 24, 2018
Researchers at the University of Exeter have found a statistical link between pneumonia in older people and a group of medicines commonly used to neutralise stomach acid in people with heartburn or stomach ulcers. Although ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.